Antibiotic Susceptibilities: Lower Respiratory Tract Isolates

The Ontario Association of Medical Laboratories (OAML) Guidelines on Antibiotic Susceptibilities represents the consensus thinking of a panel of experts in the field of Microbiology and are in keeping with the National Committee for Clinical Laboratory Standards (NCCLS)*. They have been developed to provide ordering physicians with a clear and concise reference respecting the testing and reporting of antibiotic susceptibilities of bacteria isolated from patients in the community. These guidelines are appropriate at the time of writing and are applicable in most clinical situations. However, if in doubt, referral to a specialist should be considered.

Limitations

Several important causes of community acquired pneumonia are not detected in routine cultures: *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Legionella*, respiratory viruses, and anaerobes.

<table>
<thead>
<tr>
<th>Pathogens</th>
<th>Antibiotics Reported</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Streptococcus pneumoniae</em></td>
<td>Penicillin, erythromycin, trimethoprim/sulfamethoxazole and tetracycline</td>
<td>Lower respiratory infections due to penicillin resistant strains will likely respond to high dosages of penicillin and/or amoxicillin.</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em></td>
<td>Amoxicillin/Ampicillin</td>
<td>Amoxicillin/Ampicillin susceptibility is generally predicted by the results of ß-lactamase testing. Infections due to amoxicillin resistant strains may be treated with amoxicillin/clavulanate, trimethoprim/ sulfamethoxazole, cefaclor, cefuroxime, tetracycline, clarithromycin, azithromycin, fluoroquinolones.</td>
</tr>
<tr>
<td><em>Moraxella catarrhalis</em></td>
<td>Amoxicillin/Ampicillin</td>
<td>As for <em>Haemophilus influenzae</em> plus erythromycin.</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>a) Cloxacillin**</td>
<td>a) If cloxacillin resistant the isolate is considered to be resistant to all penicillins and cephalosporins.</td>
</tr>
<tr>
<td></td>
<td>b) Erythromycin, trimethoprim/ sulfamethoxazole, clindamycin</td>
<td>b) All erythromycin resistant strains should also be considered resistant to clindamycin therapy despite results of in vitro laboratory testing.</td>
</tr>
<tr>
<td></td>
<td>c) Vancomycin</td>
<td>c) Only reported if Methicillin Resistant <em>Staphylococcus aureus</em> (MRSA).</td>
</tr>
<tr>
<td>Other gram negative aerobes</td>
<td>According to the NCCLS</td>
<td>Gram negative aerobes may be isolated from sputum specimens but rarely cause pneumonia in the community.</td>
</tr>
<tr>
<td><em>e.g. Pseudomonas aeruginosa</em>, and Enterobacteriaceae, including Klebsiella pneumoniae, etc.*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

** Cloxacillin, Oxacillin and Methicillin clinical susceptibilities are equivalent.

The Ontario Association of Medical Laboratories

The Ontario Association of Medical Laboratories (OAML) represents the community-based laboratory sector in Ontario.

Its mission is to promote excellence in the provision of laboratory services and, as an essential component of the health care system, to contribute to shaping the future of health care in Ontario.

The OAML encourages the highest level of professional and ethical integrity and technical excellence among laboratory owners, operators and staff in the provision of laboratory services for the benefit of the people of Ontario.

Guidelines for Clinical Laboratory Practice

The OAML, through its Quality Assurance and Clinical Laboratory Practice Committee, co-ordinates the development and dissemination, implementation and evaluation of Guidelines for Clinical Laboratory Practice.

A proposed Guideline is developed by a working group of the Committee with outside experts. The proposed guideline is then submitted to the Committee as a whole and to a Professional Advisory Group who provide an overall review of the document. The comments of the Committee and the Professional Advisory Group are incorporated into a revision of the guideline and this draft is submitted to laboratory Medical Directors, professional associations and other representatives of end users for additional comment. The document is revised in light of these comments and submitted to the OAML Board of Directors for approval.

Approved guidelines are distributed to Community-based Laboratories and by them to their client physicians. There may be additional educational materials produced, if it is thought that they might be useful, and these are distributed with the guideline.

The comments of end users are essential to the development of guidelines which will encourage adherence. You are strongly encouraged to submit your comments on this or on any other OAML Guideline to:

Chair
Quality Assurance and Clinical Laboratory Practice Committee
Ontario Association of Medical Laboratories
5160 Yonge Street, Suite 710
North York, Ontario
M2N 6L9

Tel: (416) 250-8555
Fax: (416) 250-8464
E-mail: oaml@oaml.com
Internet: http://www.oaml.com

Members of the Expert Panel

Julius J. Kapala, PhD, RSM (CCM)
Director of Microbiology,
Gamma-Dynacare Laboratories,
Brampton, Ontario

Baldwin Toye, MD, FRCPC
Head, Division of Microbiology and Immunology
Infectious Diseases Consultant
The Ottawa Hospital
Ottawa, Ontario

Donald E. Low, MD, FRCPC
Microbiologist-in-Chief
Mount Sinai Hospital and The Toronto Medical Laboratory, Toronto, Ontario

Alicia Sarabia, MD, FRCPC
Medical Microbiologist Consultant
MDS Laboratories Services Inc.
Toronto, Ontario

Andrew E. Simor, MD, FRCPC
Department of Microbiology
and Infectious Diseases Consultant,
Sunnybrook and Women’s College Health Sciences Centre,
Toronto, Ontario

The OAML gratefully acknowledges the contributions of the members of the Expert Panel and others who have contributed their expertise, advice and technical support to the development and review of this guideline. This guideline has been reviewed by and comments have been received from representatives of the Laboratory Medicine, Geriatrics and General and Family Practice Sections of the Ontario Medical Association and of the Laboratory Proficiency Testing Program of the OMA.

© 2000 OAML
CLP 010 Revised: March 2000